Discover how companies are responsibly integrating AI in production. This invite-only event in SF will explore the intersection of technology and business. Find out how you can attend here.
Google DeepMind and Isomorphic Labs today unveiled AlphaFold 3, a new artificial intelligence model that could greatly accelerate the development of new drugs and treatments. The research published today in Nature reveals AlphaFold 3’s unparalleled ability to predict the intricate structures and interactions of life’s essential molecules, including proteins, DNA and RNA among others.
Advanced deep learning techniques promise to rapidly advance our understanding of biology at the molecular level, and could enable scientists to pursue novel therapies for a wide range of diseases more efficiently than ever before.
Unraveling the complexities of life’s building blocks
AlphaFold 3 is the latest iteration of the groundbreaking AI system developed by Google DeepMind, building upon the success of its predecessor, AlphaFold 2. Introduced in 2020, AlphaFold 2 made significant strides in protein structure prediction, enabling scientists to make discoveries in areas ranging from malaria vaccines to cancer treatments. The impact of AlphaFold has been recognized through numerous accolades, including the 2023 Breakthrough Prize in Life Sciences.
Now, AlphaFold 3 takes this innovation even further by expanding its capabilities beyond proteins to encompass a wide array of biomolecules, including DNA, RNA and ligands. A ligand is an ion or neutral molecule that binds to a central metal atom to form a coordination complex. By accurately predicting the interactions between these molecules, AlphaFold 3 provides an unprecedented view into the complex workings of life at the molecular level.
VB Event
The AI Impact Tour – San Francisco
Join us as we navigate the complexities of responsibly integrating AI in business at the next stop of VB’s AI Impact Tour in San Francisco. Don’t miss out on the chance to gain insights from industry experts, network with like-minded innovators, and explore the future of GenAI with customer experiences and optimize business processes.
Request an invite
At t …
Article Attribution | Read More at Article Source
Discover how companies are responsibly integrating AI in production. This invite-only event in SF will explore the intersection of technology and business. Find out how you can attend here.
Google DeepMind and Isomorphic Labs today unveiled AlphaFold 3, a new artificial intelligence model that could greatly accelerate the development of new drugs and treatments. The research published today in Nature reveals AlphaFold 3’s unparalleled ability to predict the intricate structures and interactions of life’s essential molecules, including proteins, DNA and RNA among others.
Advanced deep learning techniques promise to rapidly advance our understanding of biology at the molecular level, and could enable scientists to pursue novel therapies for a wide range of diseases more efficiently than ever before.
Unraveling the complexities of life’s building blocks
AlphaFold 3 is the latest iteration of the groundbreaking AI system developed by Google DeepMind, building upon the success of its predecessor, AlphaFold 2. Introduced in 2020, AlphaFold 2 made significant strides in protein structure prediction, enabling scientists to make discoveries in areas ranging from malaria vaccines to cancer treatments. The impact of AlphaFold has been recognized through numerous accolades, including the 2023 Breakthrough Prize in Life Sciences.
Now, AlphaFold 3 takes this innovation even further by expanding its capabilities beyond proteins to encompass a wide array of biomolecules, including DNA, RNA and ligands. A ligand is an ion or neutral molecule that binds to a central metal atom to form a coordination complex. By accurately predicting the interactions between these molecules, AlphaFold 3 provides an unprecedented view into the complex workings of life at the molecular level.
VB Event
The AI Impact Tour – San Francisco
Join us as we navigate the complexities of responsibly integrating AI in business at the next stop of VB’s AI Impact Tour in San Francisco. Don’t miss out on the chance to gain insights from industry experts, network with like-minded innovators, and explore the future of GenAI with customer experiences and optimize business processes.
Request an invite
At t …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]